Isolated sixth nerve palsy after intravitreal bevacizumab injection.
OBJECTIVE
To report a case of sixth nerve palsy after intravitreal bevacuzimab injection.


METHODS
After intravitreal bevacizumab injection in a 64-year-old man, the patient admitted to our clinic with the complaint of diplopia. A complete ophthalmologic examination was done to clear the symptomatology of patient.


RESULTS
Examination of ductions revealed marked limitation of abduction of the right eye and full ductions of the left eye, consistent with right lateral rectus paralysis.


CONCLUSIONS
Although intravitreal bevacizumab injections are generally well tolerated, it is possible that some serious systemic adverse events may occur. For this reason, patients must be closely monitored following these injections.
Cakmak
Hasan Basri
HB
Atatürk Research and Training Hospital, Ankara, Turkey.
Toklu
Yasin
Y
Yorgun
Mücella Arikan
MA
Simşek
Saban
S
D020434:Abducens Nerve Diseases / Q000139:chemically induced* / Q000503:physiopathology; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis* / Q000209:etiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004948:Esotropia / Q000139:chemically induced / Q000503:physiopathology; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D056965:Injections, Intraocular; D008268:Macular Degeneration / Q000150:complications*; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab